trending Market Intelligence /marketintelligence/en/news-insights/trending/Vp8YCD-OBauKzIQ-_EtYCQ2 content esgSubNav
In This List

US FDA approves Endo's application for low blood pressure injection

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


US FDA approves Endo's application for low blood pressure injection

Endo International PLC's operating company Par Pharmaceutical received final approval from the U.S. FDA for its new drug application for ephedrine sulfate injection.

The drug is a parenterally administered pressor agent to address hypotension, which is low blood pressure, in surgical settings.

U.S. sales of ephedrine sulfate injection products were about $177 million for the 12 months ended Nov. 30, 2016, according to IMS Health data.

Par Pharmaceutical anticipates shipping of the product to begin in February.